medigraphic.com
Revista Médica Sinergia

2022, Number 07

Next >>

Revista Médica Sinergia 2022; 7 (07)

Comparative analysis between cardiovascular disease prevention guidelines in clinical, European, American and Costa Rican practice between 2016 and 2019

Benítez AMM, Sandoval EVI, Mendoza RFF

Language: Spanish
References: 35
Page:
PDF size: 275.57 Kb.


ABSTRACT

Introduction: Cardiovascular diseases have been increasing in recent years, becoming the main causes of death worldwide, this due to the impoverishment of current lifestyles that have forced them to have an accelerated rate with slight awareness of health. Among the main diseases are high blood pressure, type II diabetes, coronary heart disease and strokes. Methodology: A comparison was made between the three cardiovascular prevention guides, taking structure, content and quality as variables, for the structure and content variable, information was collected from the guides that were subsequently tabulated to observe the differences between them, for the quality variable the AGREE II instrument was used, consisting of six domains divided into 23 items, which evaluate different aspects of the guidelines, the use of the instrument required the help of four evaluators, a cardiology specialist, a general practitioner, a university intern and a medical student . Results: The Costa Rican guide in the evaluation of structure and content stood out above the other guides, by meeting the highest number of indicators, while in the quality evaluation the American guide obtained first place with 78%, followed by the guide Costa Rican with 77% and with a lower level of quality the European guide with 70%. Conclusion: The American guide stood out in the evaluation given by AGREE II in terms of quality, followed by the Costa Rican guide and finally the one with the lowest score was the European guide with significant deficiencies in content and compliance with the evaluation instrument criteria. Although the American guide obtained the best quality rating, it was not the guide with a remarkable content since the Costa Rican guide has been adapted to the current population and its diversity.


REFERENCES

  1. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. [Internet]. 2018. Disponible en: https://www.framinghamheartstudy.org/fhs-about/about-fhs-en-espanol/

  2. O"Donnel CJ, Elosua R. Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study. Rev Esp Cardiol. 2009;61(03):299–310. Disponible en: DOI: https://doi.org/10.1157/13116658

  3. Grundy SM, Bailey AL, Stone NJ. Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 25 de junio de 2019;73(24):e285–350. Disponible en: DOI: https://doi.org/10.1016/j.jacc.2018.11.002

  4. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Eur Heart J. octubre de 1998;19:1434–503. Disponible en: DOI: https://doi.org/10.1053/euhj.1998.1243

  5. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 1 de agosto de 2016;37(29):2315–81. DOI: https://doi.org/10.1093/eurheartj/ehw106

  6. Hernando S, J F, Martín Conejero A. Enfermedad arterial periférica: aspectos fisiopatológicos, clínicos y terapéuticos. Rev Esp Cardiol. 2008;60(9):969–82. DOI: https://doi.org/10.1157/13109651

  7. Jiménez MF, Castro A, Bretón I, Gomez F. Comentarios a la guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular. Rev Esp Cardiol [Internet]. 2020 [citado 3 de mayo de 2020]; Disponible en: http://www.revespcardiol.org/es-comentarios-guia-esc-2019-sobre-avance-S0300893219305500?referer=buscador

  8. Sánchez JC, Duarte M, Sánchez R, Peña N. Plan de Atención a la Salud de las Personas 2001- 2006: Caja Costarricense de Seguro Social. [Internet]. 2001. Disponible en: https://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-14292006000100003#35

  9. Sáenz MR, López E, Villalobos D, Gamboa C. Políticas Nacionales de Salud 2002-2006: Ministerio de Salud, Caja Costarricense de Seguro Social 2002. Disponible en:https://www.healthresearchweb.org/files/POLITICA_NACIONAL_SALUD_2002-2006.pdf

  10. Angulo JM, Arias M, Duarte P, Monge C. Guía para la Prevención de las Enfermedades Cardiovasculares [Internet]. 2016 [citado 6 de enero de 2022]. Disponible en: https://repositorio.binasss.sa.cr/repositorio/bitstream/handle/20.500.11764/409/2015enfermedadescardiovasculares.pdf?sequence=1&isAllowed=y

  11. Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L. AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. [Internet]. Can Med Assoc J.; 2010. Disponible en: doi: https://doi.org/10.1503/cmaj.090449

  12. Organización Panamericana de la Salud. Las ENT de un vistazo: Mortalidad de las enfermedades no transmisibles y prevalencia de sus factores de riesgo en la Región de las Américas. Washington, D.C.: OPS; 2019. Disponible en: https://iris.paho.org/handle/10665.2/51752

  13. Organizacion Mundial de la Salud. Enfermedades cardiovasculares [Internet]. Ginebra, Suiza:WHO. 2018 [citado 14 de enero 2022]. Disponible en: http://www.who.int/topics/cardiovascular_diseases/es/

  14. Marín R, Angulo JM, Duarte P. Situación Salud 2018: Ministerio de Salud. 2019. Disponible en: https://www.binasss.sa.cr/opacms/media/digitales/An%C3%A1lisis%20Integral%20de%20Situaci%C3%B3n%20de%20Salud.%20Costa%20Rica%202019.pdf

  15. José M. Romero. Enfermedad Arterial Periférica [Internet]. Medical DOSPLUS; 2010. Disponible en: http://www.podologiaeuskadi.com/Enfermedad_arterial_periferica.pdf

  16. Gonzalez Rodríguez R, Martínez Cruz M. Caracterización clínico-epidemiológica de la hipertensión arterial en adultos mayores [Internet]. Policlínico Universitario Pedro Borrás Astorga; 2017. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/520

  17. Antonio Arauz AR. Enfermedad vascular cerebral. Revista de la Facultad de Medicina de la UNAM. 2012;55:11–21. Disponible en: http://www.scielo.org.mx/scielo.php?pid=S0026-17422012000300003&script=sci_abstract

  18. Bejarano L, María J, Brotons Cuixart C. Factores de riesgo cardiovascular y atención primaria: evaluación e intervención. Aten Primaria.2010;668–77. Disponible en: doi: https://doi.org/10.1016/j.aprim.2011.10.002

  19. Humphreys J. SIAC | Nueva Guía de Hipertensión 2017 | SIAC [Internet]. [citado 3 de mayo de 2020]. Disponible en: http://www.siacardio.com/educacion/guias/nueva-guia-de-hipertension-2017/

  20. 2Alvarado MA, Angulo JM, Duarte P, Monge C. Guias para la Detección, Diagnóstico y Tratamiento de la Hipertensión Arterial: Caja Costarricense de Seguro Social; 2009. [Internet].Disponible en: https://www.binasss.sa.cr/protocolos/hipertension.pdf

  21. Burguez S. Insuficiencia cardíaca aguda. Revista Uruguaya Cardiologia. 2017;32:372–92. Disponible en: http://www.scielo.edu.uy/pdf/ruc/v32n3/1688-0420-ruc-32-03-370.pdf

  22. Lavalle Cobo A, Sanabria H. Guías sobre diabetes, prediabetes y desarrollo de enfermedad cardiovascular de la Sociedad Europea de Cardiología (ESC) en colaboración con la Asociación Europea para el Estudio Diabetes (EASD) 2019 [Internet]. Sociedad Argentina de Cardiología; 2019. Disponible en: https://www.sac.org.ar/novedades-bibliograficas/guias-diabetes-esc-2019/

  23. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J [Internet]. 2019 [citado 6 de enero de 2022]; Disponible en: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehz486/5556890

  24. Gonzalez RD. Tabaquismo o fumar tabaco es un riesgo cardiovascular: Fundacion Española del Corazon 2016 [Internet]. [citado 21 febrero del 2022]. Disponible en: http://www.fundaciondelcorazon.com/prevencion/riesgo-cardiovascular/fumar-tabaco-tabaquismo.html

  25. Liras A, Martín S. Tabaquismo: Fisiopatología y prevención. Revista de Investigacion Clínica. 2008;59:278–89. Disponible en: https://www.medigraphic.com/pdfs/revinvcli/nn-2007/nn074f.pdf

  26. Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID,Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L. INSTRUMENTO AGREE II PARA LA EVALUACIÓN DE GUÍAS DE PRÁCTICA CLÍNICA [Internet]. Consorcio AGREE; 2010. Disponible en: https://www.agreetrust.org/wp-content/uploads/2013/06/AGREE_II_Spanish.pdf

  27. [Internet] Mayo Clin Proc. 2019 [consulted Apr 22, 2022];94(12):2556–71. Doi: https://doi.org/10.1016/j.mayocp.2019.02.019

  28. D’Avino P, Serena G, Kenyon V, Fasano A. An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications. [Internet] Expert Rev Clin Immunol. 2021 [consulted Apr 22, 2022];17(3):269–84. Doi: https://doi.org/10.1080/1744666X.2021.1880320

  29. Jalilian M, Jalali R. Prevalence of celiac disease in children with type 1 diabetes: A review. [Internet] Diabetes Metab Syndr Clin Res Rev. 2021 [consulted Apr 22, 2022];15(3):969–74. Doi: https://doi.org/10.1016/j.dsx.2021.04.023

  30. Durham J, Temples HS. Celiac Disease in the Pediatric Population. J Pediatr Heal Care. 2018 [consulted Apr 22, 2022];32(6):627–31. Doi: https://doi.org/10.1016/j.pedhc.2018.04.023

  31. Brenes F, Herrera A. Contribución del Patólogo y Estudios Preliminares de la Enfermedad Celíaca en Costa Rica. En: Rodrigo L, Amado S. P, editores. Enfermedad Celíaca y Sensibilidad al Gluten No Celíaca. Barcelona, España; 2013. p. 203–18.

  32. Hill ID. Diagnosis of celiac disease in children [Internet]. UpToDate. 2021 [Consulted Apr 22, 2022]. Available from: https://www.uptodate.com/contents/diagnosis-of-celiac-disease-in-children?search=diagnosis%20of%20celiac%20disease%20in%20children&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

  33. Thomas PC, Tighe MP, Mark Beattie R. Coeliac disease in children. BMJ (Online) [Internet]. 2018 [consulted Apr 22, 2022];363:1–5. Doi: https://doi.org/10.1136/bmj.k3932

  34. Mandile R, Auricchio R. The 2020 New Espghan Guidelines For The Diagnosis Of Paediatric Coeliac Disease. [Internet] Med e Bambino. 2022 [consulted Apr 22, 2022];41(1):26–8. Doi: https://doi.org/10.53126/MEB41026

  35. Hill ID. Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children [Internet]. UpToDate. 2021 [consulted Apr 22, 2022]. Available from: https://www.uptodate.com/contents/epidemiology-pathogenesis-and-clinical-manifestations-of-celiac-disease-in-children?search=celiac%20disease%20children&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H6




2020     |     www.medigraphic.com